

---

<b>Product Name</b>	: Tozorakimab	Tozorakimab (MEDI-3506)
<b>Cat. No.</b>	: PC-24499	
<b>CAS No.</b>	: 2376858-66-9	Anti-IL-33 mAb
<b>Molecular Formula</b>	:	
<b>Molecular Weight</b>	: 144660.00	
<b>Target</b>	: Biosimilar Antibody	
<b>Solubility</b>	: 10 mM in DMSO	

### Biological Activity

Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33 (IL-33), blocks IL-33red and IL-33ox signalling, reduces inflammation and epithelial dysfunction.

Tozorakimab (MEDI-3506) inhibits reduced IL-33 (IL-33red) and oxidized IL-33 (IL-33ox) activities through distinct serum-stimulated 2 (ST2) and receptor for advanced glycation end products/epidermal growth factor receptor (RAGE/EGFR complex) signalling pathways.

Tozorakimab (MEDI-3506) has femtomolar affinity for IL-33red and a fast association rate ( $8.5 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ ), which is comparable to soluble ST2.

Tozorakimab (MEDI-3506) potently inhibits ST2-dependent inflammatory responses driven by IL-33 in primary human cells and in a murine model of lung epithelial injury.

Anti-[human IL-33], Human IgG1 lambda1, monoclonal antibody.

### References

England E, et al. Sci Rep. 2023 Jun 17;13(1):9825.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---